NantHealth & NantOmics launch AI platform for subtyping Lung Cancer

NantHealth, Inc., a personalized, evidence-based, next-generation healthcare company and NantOmics, LLC, one of the leading companies in molecular analysis, have reportedly launched an innovative AI platform for assisting pathologists in image-based lung cancer subtyping. The platform was demonstrated at the Society for IS&T’s (Imaging Science and Technology) International Symposium on Electrical Imaging 2020.

Reportedly, this AI-based platform precisely subtypes lung cancer pathology and accomplishes high concordance with analysis conducted by trained medical pathologists.

An initial study of the AI technology was presented at the sixth AACR (American Association for Cancer Research) and the IASLC (International Association for the Study of Lung Cancer) International Joint Conference. The study stated that even with lower overall tumor mutation burden (TMB) and lymphocyte levels, there is a subset of lung cancers with extremely high infiltrating lymphocyte counts.

The findings showed that an innovative Artificial Intelligence-based technique for subtyping lung cancer pathologies impacts treatment options for patients and enhanced methods of finding tumor-infiltrating white cells observed elevated in lung cancer.

Dr. Patrick Soon-Shiong, MD, CEO and Chairman of NantHealth, said that precisely quantifying and identifying tumor-infiltrating white cells is important for prognosis and treatment decisions. Still, it currently involves manual assessment of whole slide images by professional pathologists and incurs significant cost and delays.

Soon-Shiong cites that the company’s aim was to create a novel cloud-based diagnostic imaging system. To achieve this, the machine vision of digitally transferred images of tumor tissue would enable a scalable cloud-based infrastructure, with an automated, image patch-based system to categorize cancers by their immune status.

Soon-Shiong explained that with extremely accurate lymphocyte and tumor-region detection, oncologists could better treat their patients with the help of adeno versus squamous-based treatments and the use of immunotherapies could result in better outcomes.

For a record, NantOmics delivers molecular diagnostic capabilities with an aim to provide molecularly driven decision support and actionable intelligence for treating cancer. Meanwhile, NantHealth provides solutions across the continuum of care for patients, physicians, payors, patients, and biopharmaceutical organizations.
 

Source Credit: https://apnews.com/Business%20Wire/4971d90aa0794eb384e2a8c37b323622